What Vins Bioproducts does

Vins Bioproducts Limited is an Indian biopharmaceutical manufacturer founded in 1997 and headquartered at Thimmapur, Telangana, that develops and commercializes equine-derived immunoglobulins and antisera. Its product portfolio spans three categories: anti-venoms (ASVS, BIOSNAKE, AFRIVEN, ECHIVEN, PCAS, MENASCORP, MENASCORP Plus) targeting snake and scorpion envenomation across India, Africa, the MENA region, and the Philippines; anti-virals (VINRAB and VINRIG equine rabies immunoglobulins, plus VINCOV-19 F(ab')2 COVID-19 therapeutic); and anti-bacterials (TETAVIN, VINDIP, GANGREVIN) for tetanus, diphtheria, and gas gangrene.

The core technology platform is equine hyperimmunization combined with downstream plasma fractionation, pepsin digestion, controlled heating, caprylic acid precipitation, ultra-filtration, and sterile filtration to produce F(ab')2 immunoglobulin fragments. The company operates a vertically integrated supply chain across 150-acre farms housing 2,000+ equines and two GMP manufacturing plants with combined capacity of 10 million units per annum. Regulatory credentials include WHO GMP (since 2002), PIC/s GMP (since 2018), DSIR-recognition of in-house R&D (since 2009), and product registrations across more than 110 countries.

The business model is enterprise/government field sales. Revenue is generated through unit-priced sales of liquid and lyophilized biologicals via direct procurement contracts with national and state governments, ministries of health, and international agencies including WHO, UNICEF, UNDP, and PAHO. Pricing is contract-negotiated and not publicly disclosed. The company is privately held, controlled by the Daga family through the ViNS Group conglomerate (1,500+ employees across pharmaceuticals, diagnostics, and real estate), and in December 2025 deployed Rs 150 crore as lead investor in PlasmaGen Biosciences, signalling vertical interest in plasma fractionation.

Name

Vins Bioproducts

Legal name

ViNS Bioproducts Ltd

Website

https://vinsbio.in

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Vins Bioproducts Limited is an Indian biopharmaceutical company founded in 1997 that manufactures equine-derived antisera and immunoglobulins — anti-venoms, anti-toxins, and anti-viral products — supplying governments, hospitals, and international health agencies across 110+ countries from a 150-acre facility in Telangana with PIC/s GMP certification.

Ownership category

akta.pro rank

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Biological Pharmaceuticals and Antisera Sales: Revenue is generated through the sale of equine-derived biological products including antivenoms, antitoxins, and immunoglobulins to governments, healthcare institutions, and international organizations. Products are sold in both liquid and lyophilized forms across 110+ countries.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Vins Bioproducts develops and manufactures equine-derived antisera and immunoglobulin products for the treatment of snake bites, scorpion stings, rabies, tetanus, diphtheria, and gas gangrene. The company operates an integrated supply chain from a 150-acre equine farm housing 2,000+ horses for plasma collection through WHO GMP-certified manufacturing facilities producing up to 10 million units per annum, with products supplied in liquid and lyophilized forms across 110+ countries.

Product overview

Vins Bioproducts Limited is a biopharmaceutical company specializing in equine immunoglobulins and antisera products. Founded in 1997 and headquartered in Telangana, India, the company operates WHO GMP-certified manufacturing facilities and supplies products to over 110 countries globally. The product portfolio is organized into three main categories: (1) Anti-Venom products including ASVS, BIOSNAKE, AFRIVEN, ECHIVEN, PCAS, MENASCORP, and MENASCORP Plus for snake and scorpion envenomation treatment; (2) Anti-Viral products including VINRAB and VINRIG rabies immunoglobulins and VINCOV-19 COVID-19 therapeutic; and (3) Anti-Bacterial products including TETAVIN tetanus antitoxin, VINDIP diphtheria antitoxin, and GANGREVIN gas-gangrene antitoxin. The company operates 150-acre farms with over 2,000 equines for plasma collection and maintains a Thimmapur facility with two manufacturing plants producing up to 10 million units per annum.

Differentiator

Problem solved

Functional benefit

Brands

• ASVS (Snake Venom Antiserum I.P): Snake Venom Antiserum (Polyvalent) - refined and concentrated preparation of serum globulins obtained by fractionating blood from healthy hyperimmunised horses. Available in Lyophilized and Liquid forms.
• BIOSNAKE (Snake Venom Antitoxin I.H.S)
• AFRIVEN
• ECHIVEN
• PCAS
• MENASCORP
• MENASCORP Plus
• VINRAB
• VINRIG
• VINCOV-19
• TETAVIN
• VINDIP
• GANGREVIN

Products and services

• ASVS (Snake Venom Antiserum I.P) Polyvalent snake venom antiserum that is a refined and concentrated preparation of serum globulins obtained by fractionating blood from healthy hyperimmunised horses. Neutralizes venoms from Indian Cobra, Common Krait, Russell's Viper, and Saw-scaled Viper. Available in lyophilized and liquid forms in 10 ml glass vials.
• BIOSNAKE (Snake Venom Antitoxin I.H.S) Snake venom antitoxin polyvalent prepared from purified plasma of healthy horses hyperimmunized against African snake venoms (Naja haje, Naja nigricollis, Cerastes Cerastes). Purified by pepsin digestion, controlled heating, caprylic acid precipitation, ultra-filtration and sterile filtration. Presented in 20 ml glass vials.
• AFRIVEN (Snake Venom Antiserum African 10 I.H.S) Lyophilized sterile preparation containing equine immunoglobulin fragments F(ab')2 for African snakes. Neutralizes venoms from VIPERIDAE species (Echis ocellatus, Bitis species) and ELAPIDAE species (Dendroaspis, Naja species). Reconstituted with 10 ml sterilised water for injections.
• ECHIVEN (Snake Venom Antiserum ECHIS I.H.S)

Quantifiable outcome

• Supplies to over 110 countries across Asia, Africa, Middle East, Europe, Australia, North America, and South America
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core.

• University of Hyderabad (UoH)coreStrategic or Co-development Partner · 1 January 2021Collaboration with University of Hyderabad and CSIR-CCMB in the development of VINCOV-19, an antidote and cure against SARS-CoV-2, described as the country's first such solution. Phase 2 clinical trials of VINCOV-19 were successfully completed in 2022.
• CSIR-Centre for Cellular & Molecular Biology (CCMB)coreStrategic or Co-development Partner · 1 January 2021Co-development partnership with CSIR-CCMB and University of Hyderabad for VINCOV-19, an equine anti-COVID antibody F(ab')2 product, with successful Phase 2 clinical trial completion in 2022.
• WHO (World Health Organization)coreStrategic or Co-development PartnerViNS Bioproducts collaborates with WHO to ensure the widespread distribution of life-saving antisera and antivenom products globally. WHO partnership serves as a key reference for the company's quality standards and international credibility.
• UNICEFcoreStrategic or Co-development PartnerViNS Bioproducts collaborates with UNICEF for the supply and distribution of antivenom and immunization products to address public health needs in developing countries.
• UNDP (United Nations Development Programme)coreStrategic or Co-development PartnerPartnership with UNDP for distribution of life-saving biological products to address healthcare needs in emerging markets.
• PAHO (Pan American Health Organization)coreStrategic or Co-development PartnerCollaboration with PAHO for supply and distribution of antivenom and antisera products across the Americas.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/VinsBioproducts
• Facebookfacebook.com/600541490149454
• LinkedInlinkedin.com/company/vins-bioproducts-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vins Bioproducts